Showing results (51-60 of 77) with videos related to
Sort By:
Pageof 8
Neurology|July 13, 2000
Psychological stress and the subsequent appearance of new brain MRI lesions in MSD C Mohr, D E Goodkin, P Bacchetti, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|February 13, 1999
Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1aD C Mohr, W Likosky, A C Boudewyn, et al.Neurology|October 26, 1999
Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosisE Waubant, D E Goodkin, L Gee, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 17, 1999
Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosisD C Mohr, D E Goodkin, L Masuoka, et al.Annals of Neurology|January 1, 1995
Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosisD E Goodkin, R A Rudick, S VanderBrug Medendorp, et al.Lancet (London, England)|October 26, 1991
Overview of azathioprine treatment in multiple sclerosisP L Yudkin, G W Ellison, A Ghezzi, et al.Neurology|September 26, 2002
Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MSR G Ghalie, G Edan, M Laurent, et al.The Online Journal of Current Clinical Trials|September 25, 1992
Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicityD E Goodkin, R A Rudick, S VanderBrug Medendorp, et al.Neurology|July 23, 1998
A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosisD E Goodkin, R P Kinkel, B Weinstock-Guttman, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|June 29, 2000
1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MSJ Suhy, W D Rooney, D E Goodkin, et al.Pageof 8